This SBIR phase II proposal is aimed at developing microarray technology to study the interactions between heparan sulfate (HS) and proteins. HS is a highly sulfated polysaccharide displaying a wide range of biological functions. There is a strong demand in the research community for a high throughput method to study the binding between HS and proteins. During the previously funded phase I study (R41GM123792), Glycan Therapeutics has developed and launched a pilot HS microarray service. The outcome from the STTR grant clearly demonstrates that the research community greatly appreciates a convenient and reliable HS microarray service. This phase II application is focused on the expansion of the HS microarray service.
Aim 1 is designed to expand the HS oligosaccharide library from 95 to 250 structures. A larger number of HS oligosaccharides on the microarray will enhance its ability to study the relationship between the function and structure of HS saccharide sequences.
Aim 2 will develop a bioinformatic approach to structurally triage the oligosaccharides based on microarray data. The bioinformatic method is expected to predict additional structures that may interact with the target proteins. A streamlined website will simplify data presentation for end users to acquire the data without technical complexity. Our success will lead to a convenient and reliable research tool for advancing glycosciences.

Public Health Relevance

Heparan sulfate is a sulfated polysaccharide displaying a wide range of biological functions. In this project, Glycan Therapeutics plans to develop an innovative heparan sulfate microarray technology. The success of the project will provide a new tool to study the interactions between heparan sulfate and proteins to advance glycoscience research.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44GM123792-03
Application #
10005531
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Bond, Michelle Rueffer
Project Start
2017-09-01
Project End
2022-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Glycan Therapeutics, LLC
Department
Type
DUNS #
078778864
City
Raleigh
State
NC
Country
United States
Zip Code
27606